EUROSSTEM is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety
Post market observational study. This study is multicenter, prospective, non comparative.
Study Type
OBSERVATIONAL
Enrollment
131
Hip prosthesis surgery
Clinique du Mail
Puilboreau, La Rochelle, France
Clinique Esquirol St Hilaire
Agen, France
CH Aix en Provence
Aix-en-Provence, France
Polyclinique du Beaujolais
Arnas, France
Clinique Montagard
Avignon, France
Polyclinique du Parc Drevon
Dijon, France
Clinique du Palais
Grasse, France
Hôpital privé Drôme Ardèche - Clinique Pasteur
Guilherand-Granges, France
Clinique Richelieu
Saintes, France
Safety of EUROSTEM Femoral Stem
Collect the safety of the device trought complications occurence rate
Time frame: 1 year
Radiological performances of EUROSTEM Femoral Stem
Collect the performances of the device trought radiological evaluation
Time frame: 1 year
Clinical performances of EUROSTEM Femoral Stem
Collect the performances of the device trought clinical scores
Time frame: 1 year
Survival of EUROSTEM Femoral Stem
Assess the survival rate of the device
Time frame: 10 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.